Wealth Enhancement Advisory Services LLC Buys 146 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Wealth Enhancement Advisory Services LLC grew its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 0.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 30,597 shares of the company’s stock after buying an additional 146 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in GE HealthCare Technologies were worth $2,392,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Quent Capital LLC grew its holdings in GE HealthCare Technologies by 18.4% during the 3rd quarter. Quent Capital LLC now owns 766 shares of the company’s stock worth $72,000 after acquiring an additional 119 shares during the period. Greenleaf Trust grew its stake in GE HealthCare Technologies by 1.7% during the third quarter. Greenleaf Trust now owns 7,619 shares of the company’s stock worth $715,000 after purchasing an additional 124 shares during the period. Westside Investment Management Inc. increased its holdings in GE HealthCare Technologies by 32.0% in the third quarter. Westside Investment Management Inc. now owns 516 shares of the company’s stock worth $48,000 after purchasing an additional 125 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in GE HealthCare Technologies by 8.7% in the second quarter. EverSource Wealth Advisors LLC now owns 1,590 shares of the company’s stock valued at $135,000 after buying an additional 127 shares during the period. Finally, Quarry LP boosted its holdings in shares of GE HealthCare Technologies by 28.3% during the 2nd quarter. Quarry LP now owns 594 shares of the company’s stock worth $46,000 after buying an additional 131 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.

GE HealthCare Technologies Trading Down 1.4 %

Shares of GE HealthCare Technologies stock opened at $84.13 on Wednesday. The company has a market capitalization of $38.44 billion, a P/E ratio of 23.11, a price-to-earnings-growth ratio of 2.90 and a beta of 1.11. The stock has a fifty day simple moving average of $82.13 and a 200 day simple moving average of $84.27. GE HealthCare Technologies Inc. has a 12-month low of $71.31 and a 12-month high of $94.55. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.08. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The firm had revenue of $4.86 billion during the quarter, compared to analyst estimates of $4.87 billion. During the same quarter in the prior year, the business posted $0.99 EPS. The business’s revenue was up .9% compared to the same quarter last year. On average, sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Tuesday, January 14th will be paid a $0.035 dividend. This is a positive change from GE HealthCare Technologies’s previous quarterly dividend of $0.03. The ex-dividend date of this dividend is Tuesday, January 14th. This represents a $0.14 annualized dividend and a yield of 0.17%. GE HealthCare Technologies’s dividend payout ratio (DPR) is 3.85%.

Insiders Place Their Bets

In related news, CEO Roland Rott sold 3,577 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the sale, the chief executive officer now directly owns 24,298 shares of the company’s stock, valued at approximately $2,101,291.04. This trade represents a 12.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

GEHC has been the subject of several research analyst reports. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and lifted their price objective for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th. UBS Group downgraded shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and decreased their price target for the company from $84.00 to $74.00 in a research note on Thursday, September 26th. BTIG Research raised shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research report on Wednesday, September 18th. Stifel Nicolaus boosted their target price on GE HealthCare Technologies from $100.00 to $102.00 and gave the company a “buy” rating in a research report on Monday, September 30th. Finally, Wells Fargo & Company increased their price target on GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $96.00.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.